AQP4 and neuromyelitis optica: Very recent research has highlighted a novel potential therapeutic approach utilising small-molecule inhibitors to reduce AQP4 mediated astrocyte cytotoxicity by disrupting the interaction between NMO-IgG and M23-AQP4 [154].